What CytomX Therapeutics, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 6 |
| Total trades | 1 | 13 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 100,000 | 656,793 |
| Disposed | 0 | 294,480 |
| Net activity | +100,000 | +362,313 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Carvajal Alejandra | Chief Legal Officer | Aug 03 | Grant / award · A | +100,000 | — | — | 100,000 |
| Ogden Christopher | Chief Financial Officer | Jun 15 | Open-market sale · S | −1,624 | $3.05 | −$4.95K | 295,324 |
| Ogden Christopher | Chief Financial Officer | Mar 17 | Open-market sale · S | −19,323 | $6.42 | −$124K | 296,948 |
| McCarthy Sean A. | CEO | Mar 17 | Open-market sale · S | −118,969 | $6.42 | −$764K | 1,078,922 |
| Chu Yu-Waye | Chief Medical Officer | Mar 17 | Open-market sale · S | −21,279 | $6.42 | −$137K | 189,446 |
| Belvin Marcia | SVP, Chief Scientific Officer | Mar 17 | Open-market sale · S | −31,492 | $6.42 | −$202K | 300,760 |
| Ogden Christopher | Chief Financial Officer | Feb 02 | Grant / award · A | +90,000 | — | — | 316,271 |
| McCarthy Sean A. | CEO | Feb 02 | Grant / award · A | +210,000 | — | — | 1,197,891 |
| Chu Yu-Waye | Chief Medical Officer | Feb 02 | Grant / award · A | +75,000 | — | — | 210,725 |
| Belvin Marcia | SVP, Chief Scientific Officer | Feb 02 | Grant / award · A | +60,000 | — | — | 332,252 |
| Lester Rachael | Chief Business Officer | Feb 02 | Grant / award · A | +20,000 | — | — | 20,000 |
| McCarthy Sean A. | CEO | Nov 06 | Disclosed 10b5-1 sale · S | −101,793 | $4.54 | −$462K | 1,089,684 |
| McCarthy Sean A. | CEO | Nov 06 | Exercise / conversion · M | +101,793 | $1.59 | +$162K | 1,191,477 |
| Ogden Christopher | Chief Financial Officer | Jun 16 | Open-market sale · S | −10,614 | $2.69 | −$28.5K | 226,271 |
| McCarthy Sean A. | CEO | Jun 16 | Open-market sale · S | −55,511 | $2.69 | −$149K | 1,089,684 |
| Belvin Marcia | SVP, Chief Scientific Officer | Jun 16 | Open-market sale · S | −13,884 | $2.69 | −$37.3K | 272,252 |
| Ogden Christopher | Chief Financial Officer | Jun 13 | Exercise / conversion · M | +37,500 | — | — | 236,885 |
| Ogden Christopher | Chief Financial Officer | Jun 13 | Open-market sale · S | −1,641 | $2.95 | −$4.84K | 199,385 |
| McCarthy Sean A. | CEO | Jun 13 | Exercise / conversion · M | +150,000 | — | — | 1,145,195 |
| Belvin Marcia | SVP, Chief Scientific Officer | Jun 13 | Exercise / conversion · M | +37,500 | — | — | 286,136 |
Loading...
